SG10202013034QA - Compositions, devices, and methods for the treatment of alcohol use disorder - Google Patents
Compositions, devices, and methods for the treatment of alcohol use disorderInfo
- Publication number
- SG10202013034QA SG10202013034QA SG10202013034QA SG10202013034QA SG10202013034QA SG 10202013034Q A SG10202013034Q A SG 10202013034QA SG 10202013034Q A SG10202013034Q A SG 10202013034QA SG 10202013034Q A SG10202013034Q A SG 10202013034QA SG 10202013034Q A SG10202013034Q A SG 10202013034QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treatment
- methods
- devices
- alcohol use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354465P | 2016-06-24 | 2016-06-24 | |
| US201662419736P | 2016-11-09 | 2016-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202013034QA true SG10202013034QA (en) | 2021-02-25 |
Family
ID=60784803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202013034QA SG10202013034QA (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
| SG11201811580SA SG11201811580SA (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811580SA SG11201811580SA (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190209464A1 (en) |
| EP (1) | EP3474842A4 (en) |
| JP (2) | JP2019520361A (en) |
| KR (2) | KR102453781B1 (en) |
| CN (1) | CN109789122A (en) |
| AU (2) | AU2017281941A1 (en) |
| CA (1) | CA3028731A1 (en) |
| MX (2) | MX2018015985A (en) |
| PH (1) | PH12018502738A1 (en) |
| RU (2) | RU2767062C2 (en) |
| SG (2) | SG10202013034QA (en) |
| WO (1) | WO2017223566A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102453781B1 (en) * | 2016-06-24 | 2022-10-12 | 오피언트 파마슈티컬스, 인코퍼레이티드 | Compositions, devices and methods for the treatment of alcohol use disorders |
| EP3538189A4 (en) * | 2016-11-09 | 2020-04-22 | Opiant Pharmaceuticals, Inc. | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions |
| US11458091B2 (en) | 2016-11-18 | 2022-10-04 | Opiant Pharmaceuticals, Inc. | Compositions and methods for the treatment of opioid overdose |
| EP3793558A4 (en) * | 2018-05-17 | 2022-04-20 | Aegis Therapeutics, LLC | Formulations and methods for the prevention of opioid overdose |
| SG11202106531VA (en) * | 2018-12-20 | 2021-07-29 | Aegis Therapeutics Llc | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
| CA3138846A1 (en) * | 2019-05-16 | 2020-11-19 | Shin Nippon Biomedical Laboratories, Ltd. | Powder formulation for intranasal administration, and manufacturing method thereof |
| WO2023147443A2 (en) * | 2022-01-26 | 2023-08-03 | Tulex Pharmaceuticals Inc. | Novel compositions |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4882335A (en) * | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US5069895A (en) * | 1989-11-09 | 1991-12-03 | Diamond Ivan F | Methods for the treatment of alcohol intoxication and dependence |
| EP0444778A1 (en) * | 1990-02-14 | 1991-09-04 | Alcon Laboratories, Inc. | Use of alkyl saccharides to enhance the penetration of drugs |
| JP2005508888A (en) * | 2001-08-14 | 2005-04-07 | バイオティ セラピーズ コーポレイション | How to treat alcoholism or alcoholism |
| US9895444B2 (en) * | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US20070212307A1 (en) * | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
| WO2008095086A2 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| JP2010537990A (en) * | 2007-08-27 | 2010-12-09 | ユニバーシティ オブ バージニア パテント ファウンデーション | Medicinal combination for the treatment of alcohol addiction and drug addiction |
| US9149557B2 (en) * | 2008-04-16 | 2015-10-06 | The Chemo-Sero-Therapeutic Research Institute | Process for preparing bioabsorbable sheet preparation holding thrombin |
| CN103384513B (en) * | 2010-10-29 | 2016-01-13 | 特罗伊卡药品有限公司 | The nasal composition of vitamin B12 |
| AR086391A1 (en) * | 2011-05-13 | 2013-12-11 | Euro Celtique Sa | INTRANASAL PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE NALOXONE |
| US10485798B2 (en) * | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| US20140171458A1 (en) * | 2012-12-13 | 2014-06-19 | 3B Pharmaceuticals, Inc. | Intranasal naltrexone |
| DE202013105715U1 (en) * | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Device for delivering a predetermined amount of a substance to a natural opening of the body |
| US9480644B2 (en) * | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| KR102453781B1 (en) * | 2016-06-24 | 2022-10-12 | 오피언트 파마슈티컬스, 인코퍼레이티드 | Compositions, devices and methods for the treatment of alcohol use disorders |
-
2017
- 2017-06-26 KR KR1020197001264A patent/KR102453781B1/en active IP Right Grant
- 2017-06-26 MX MX2018015985A patent/MX2018015985A/en unknown
- 2017-06-26 CN CN201780044057.3A patent/CN109789122A/en active Pending
- 2017-06-26 RU RU2019101810A patent/RU2767062C2/en active
- 2017-06-26 RU RU2022103366A patent/RU2022103366A/en unknown
- 2017-06-26 SG SG10202013034QA patent/SG10202013034QA/en unknown
- 2017-06-26 AU AU2017281941A patent/AU2017281941A1/en not_active Abandoned
- 2017-06-26 US US16/311,944 patent/US20190209464A1/en active Pending
- 2017-06-26 SG SG11201811580SA patent/SG11201811580SA/en unknown
- 2017-06-26 JP JP2018567665A patent/JP2019520361A/en active Pending
- 2017-06-26 CA CA3028731A patent/CA3028731A1/en active Pending
- 2017-06-26 EP EP17816377.0A patent/EP3474842A4/en active Pending
- 2017-06-26 KR KR1020227034876A patent/KR102634829B1/en active IP Right Grant
- 2017-06-26 WO PCT/US2017/039300 patent/WO2017223566A1/en unknown
-
2018
- 2018-12-18 MX MX2022013671A patent/MX2022013671A/en unknown
- 2018-12-21 PH PH12018502738A patent/PH12018502738A1/en unknown
-
2022
- 2022-03-31 JP JP2022058125A patent/JP2022088592A/en active Pending
-
2023
- 2023-04-20 AU AU2023202420A patent/AU2023202420A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102453781B1 (en) | 2022-10-12 |
| MX2018015985A (en) | 2019-09-13 |
| MX2022013671A (en) | 2022-12-13 |
| EP3474842A4 (en) | 2020-01-29 |
| RU2019101810A3 (en) | 2020-10-14 |
| RU2022103366A (en) | 2022-03-01 |
| AU2023202420A1 (en) | 2023-05-11 |
| WO2017223566A1 (en) | 2017-12-28 |
| AU2017281941A1 (en) | 2019-02-07 |
| KR20220167279A (en) | 2022-12-20 |
| JP2019520361A (en) | 2019-07-18 |
| KR102634829B1 (en) | 2024-02-07 |
| US20190209464A1 (en) | 2019-07-11 |
| SG11201811580SA (en) | 2019-01-30 |
| RU2767062C2 (en) | 2022-03-16 |
| KR20190055057A (en) | 2019-05-22 |
| JP2022088592A (en) | 2022-06-14 |
| EP3474842A1 (en) | 2019-05-01 |
| CA3028731A1 (en) | 2017-12-28 |
| CN109789122A (en) | 2019-05-21 |
| PH12018502738A1 (en) | 2019-10-21 |
| RU2019101810A (en) | 2020-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258205A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| IL264049A (en) | Compounds, compositions, and methods for the treatment of disease | |
| IL264156A (en) | Compounds, compositions, and methods for the treatment of disease | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| EP3151797A4 (en) | Methods and devices for treating the skin | |
| SG10202013034QA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| HK1259372A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
| IL290150A (en) | Compositions and methods for the treatment of chronic pain | |
| GB2588261B (en) | Apparatus, use of the apparatus and arrangement | |
| EP3538189A4 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| EP3328864A4 (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| IL287621A (en) | Compositions and methods for the treatment of fungal infections | |
| ZA201808232B (en) | Compositions and methods for the treatment of cancer | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| EP3341006A4 (en) | Compositions and methods for the treatment of neurodamage | |
| HK1255695A1 (en) | Composition and methods for the treatment of blepharoptosis | |
| EP3373920A4 (en) | Methods and compositions for treating alcohol use disorders | |
| HUE054756T2 (en) | Treatment of alcohol use disorder | |
| ZA201802201B (en) | Novel formulation and treatment methods | |
| SG11201704282UA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| AU2015902659A0 (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders |